Status:

COMPLETED

A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed

Lead Sponsor:

Janssen Research & Development, LLC

Conditions:

HIV

Eligibility:

All Genders

2-11 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to evaluate the steady state pharmacokinetics (PK) of rilpivirine (RPV) and determine the appropriate dose of RPV in combination with other antiretrovirals (ARVs) in parti...

Detailed Description

Participants infected with human immunodeficiency virus type 1 (HIV-1) are routinely treated with combinations of multiple drugs which reduces HIV-1 ribonucleic acid (RNA) to undetectable levels in a ...

Eligibility Criteria

Inclusion

  • Weighing at least 10 kilogram (kg) at screening
  • Have documented chronic Human Immunodeficiency Virus (HIV-1) infection
  • On a stable antiretroviral (ARV) regimen for at least 6 months prior to screening and virologically suppressed with documented evidence of at least 2 plasma viral loads less than (\<) 50 HIV-1 ribonucleic acid (RNA) copies/milliliter (mL): one within 2-12 months prior to screening and one at screening
  • Can switch from any ARV class
  • Never been treated with a therapeutic HIV vaccine
  • Historical HIV-1 genotyping result at screening for children aged \>=2 to \<6 years (and for children aged \>=6 to \<12 years if a historical HIV-1 genotyping result is available at screening) must demonstrate sensitivity to RPV and to the selected background ARVs

Exclusion

  • Have previously documented HIV-2 infection
  • Have known or suspected acute (primary) HIV-1 infection
  • Taken any disallowed concomitant therapies within 4 weeks before the planned first dose of study intervention
  • Any current or history of adrenal disorder
  • A history of virologic failure to ARVs with or without availability of an HIV-1 genotype result at the time of failure

Key Trial Info

Start Date :

July 18 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 23 2023

Estimated Enrollment :

26 Patients enrolled

Trial Details

Trial ID

NCT04012931

Start Date

July 18 2019

End Date

February 23 2023

Last Update

February 4 2025

Active Locations (14)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (14 locations)

1

ASST Spedali Civili di Brescia

Brescia, Italy, 25123

2

Azienda Ospedaliera Universitaria Federico II

Napoli, Italy, 80131

3

IRCCS Ospedale Pediatrico Bambino Gesu

Roma, Italy, 00165

4

Uls Santa Maria - Hosp. Santa Maria

Lisbon, Portugal, 1649 035